← Back to patent-cliff list
CPL-500036
Tier C — Watch / tradeCPL-500036
Celon Pharma Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：PDE10A
Indications (approved)：Parkinson's disease, Drug-induced dyskinesia, Schizophrenia
Regional status
US
-
EU
Phase II
2021-05-19
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CPL-500036?
Approved indications include: Parkinson's disease, Drug-induced dyskinesia, Schizophrenia.
When does the CPL-500036 patent expire?
No public expiry year is available for CPL-500036 yet; this page updates once verified.
How do I get a quote for CPL-500036 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21